Medicinal chemistry of a2B adenosine receptors

Christa E. Müller, Younis Baqi, Sonja Hinz, Vigneshwaran Namasivayam

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

A2B adenosine receptors (A2BARs) are in the focus of interest as drug targets in (immuno)oncology since antagonists show anti-proliferative, anti-angiogenic, anti-metastatic, and immunostimulatory properties. Additional (poten-tial) indications for A2BAR antagonists include inflammatory (pulmonary, colon) and autoimmune diseases, pain, fibrosis, infectious diseases, diabetes, and more. Agonists were found to exhibit cardioprotective properties. The A2BAR is most closely related to the A2AAR subtype. Both are Gs protein-coupled receptors, but the A2BAR is additionally coupled to Gq proteins. A2BAR expression is upregulated under pathological conditions (hypoxia, inflammation, ischemia) and on many cancer cells. A2BARs form stable heteromeric complexes with A2AARs when co-expressed, and thereby completely block A2AAR signaling. There is still a lack of potent, selective, and fully efficacious A2BAR agonists, while structurally diverse potent and selective competitive antagonists for A2BARs have become available. The first positive and negative allosteric modulators for A2BARs were recently described. For the labeling of A2BARs, antagonist radioligands have been developed, and recently the first potent and selective fluorescent ligands were reported.

Original languageEnglish
Pages (from-to)137-168
Number of pages32
JournalReceptors
Volume34
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Adenosine A2B Receptors
Purinergic P1 Receptors
Pharmaceutical Chemistry
Adenosine A2 Receptor Antagonists
Adenosine A2 Receptor Agonists
Gq-G11 GTP-Binding Protein alpha Subunits
Lung Diseases
Autoimmune Diseases
Communicable Diseases
Colon
Fibrosis
Ischemia
Ligands
Inflammation
Pain

Keywords

  • A adenosine receptor
  • Agonist
  • Antagonist
  • Cancer
  • Inflammation
  • Structure

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Medicinal chemistry of a2B adenosine receptors. / Müller, Christa E.; Baqi, Younis; Hinz, Sonja; Namasivayam, Vigneshwaran.

In: Receptors, Vol. 34, 01.01.2018, p. 137-168.

Research output: Contribution to journalArticle

Müller, CE, Baqi, Y, Hinz, S & Namasivayam, V 2018, 'Medicinal chemistry of a2B adenosine receptors', Receptors, vol. 34, pp. 137-168. https://doi.org/10.1007/978-3-319-90808-3_6
Müller, Christa E. ; Baqi, Younis ; Hinz, Sonja ; Namasivayam, Vigneshwaran. / Medicinal chemistry of a2B adenosine receptors. In: Receptors. 2018 ; Vol. 34. pp. 137-168.
@article{97a920584f064e0d9a418246a355b6b6,
title = "Medicinal chemistry of a2B adenosine receptors",
abstract = "A2B adenosine receptors (A2BARs) are in the focus of interest as drug targets in (immuno)oncology since antagonists show anti-proliferative, anti-angiogenic, anti-metastatic, and immunostimulatory properties. Additional (poten-tial) indications for A2BAR antagonists include inflammatory (pulmonary, colon) and autoimmune diseases, pain, fibrosis, infectious diseases, diabetes, and more. Agonists were found to exhibit cardioprotective properties. The A2BAR is most closely related to the A2AAR subtype. Both are Gs protein-coupled receptors, but the A2BAR is additionally coupled to Gq proteins. A2BAR expression is upregulated under pathological conditions (hypoxia, inflammation, ischemia) and on many cancer cells. A2BARs form stable heteromeric complexes with A2AARs when co-expressed, and thereby completely block A2AAR signaling. There is still a lack of potent, selective, and fully efficacious A2BAR agonists, while structurally diverse potent and selective competitive antagonists for A2BARs have become available. The first positive and negative allosteric modulators for A2BARs were recently described. For the labeling of A2BARs, antagonist radioligands have been developed, and recently the first potent and selective fluorescent ligands were reported.",
keywords = "A adenosine receptor, Agonist, Antagonist, Cancer, Inflammation, Structure",
author = "M{\"u}ller, {Christa E.} and Younis Baqi and Sonja Hinz and Vigneshwaran Namasivayam",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/978-3-319-90808-3_6",
language = "English",
volume = "34",
pages = "137--168",
journal = "Receptors",
issn = "1048-6909",
publisher = "Humana Press",

}

TY - JOUR

T1 - Medicinal chemistry of a2B adenosine receptors

AU - Müller, Christa E.

AU - Baqi, Younis

AU - Hinz, Sonja

AU - Namasivayam, Vigneshwaran

PY - 2018/1/1

Y1 - 2018/1/1

N2 - A2B adenosine receptors (A2BARs) are in the focus of interest as drug targets in (immuno)oncology since antagonists show anti-proliferative, anti-angiogenic, anti-metastatic, and immunostimulatory properties. Additional (poten-tial) indications for A2BAR antagonists include inflammatory (pulmonary, colon) and autoimmune diseases, pain, fibrosis, infectious diseases, diabetes, and more. Agonists were found to exhibit cardioprotective properties. The A2BAR is most closely related to the A2AAR subtype. Both are Gs protein-coupled receptors, but the A2BAR is additionally coupled to Gq proteins. A2BAR expression is upregulated under pathological conditions (hypoxia, inflammation, ischemia) and on many cancer cells. A2BARs form stable heteromeric complexes with A2AARs when co-expressed, and thereby completely block A2AAR signaling. There is still a lack of potent, selective, and fully efficacious A2BAR agonists, while structurally diverse potent and selective competitive antagonists for A2BARs have become available. The first positive and negative allosteric modulators for A2BARs were recently described. For the labeling of A2BARs, antagonist radioligands have been developed, and recently the first potent and selective fluorescent ligands were reported.

AB - A2B adenosine receptors (A2BARs) are in the focus of interest as drug targets in (immuno)oncology since antagonists show anti-proliferative, anti-angiogenic, anti-metastatic, and immunostimulatory properties. Additional (poten-tial) indications for A2BAR antagonists include inflammatory (pulmonary, colon) and autoimmune diseases, pain, fibrosis, infectious diseases, diabetes, and more. Agonists were found to exhibit cardioprotective properties. The A2BAR is most closely related to the A2AAR subtype. Both are Gs protein-coupled receptors, but the A2BAR is additionally coupled to Gq proteins. A2BAR expression is upregulated under pathological conditions (hypoxia, inflammation, ischemia) and on many cancer cells. A2BARs form stable heteromeric complexes with A2AARs when co-expressed, and thereby completely block A2AAR signaling. There is still a lack of potent, selective, and fully efficacious A2BAR agonists, while structurally diverse potent and selective competitive antagonists for A2BARs have become available. The first positive and negative allosteric modulators for A2BARs were recently described. For the labeling of A2BARs, antagonist radioligands have been developed, and recently the first potent and selective fluorescent ligands were reported.

KW - A adenosine receptor

KW - Agonist

KW - Antagonist

KW - Cancer

KW - Inflammation

KW - Structure

UR - http://www.scopus.com/inward/record.url?scp=85052243403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052243403&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-90808-3_6

DO - 10.1007/978-3-319-90808-3_6

M3 - Article

VL - 34

SP - 137

EP - 168

JO - Receptors

JF - Receptors

SN - 1048-6909

ER -